# CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

> **NCT07449923** · PHASE3 · RECRUITING · sponsor: **EyePoint Pharmaceuticals, Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Diabetic Macular Edema
- DME
- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** EYP-1901
- **DRUG:** Aflibercept (2.0 mg)

## Key facts

- **NCT ID:** NCT07449923
- **Lead sponsor:** EyePoint Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-09
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07449923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07449923, "CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07449923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*